Komori
Earnings4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income)

The Company sold 1 listed security it held, generating a gain on sale of ¥220 million. The gain is scheduled to be recognized as extraordinary income in the financial results for the fourth quarter of the fiscal year ending March 2025.

Worth reading
76Important
Scored from 1 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
220
¥ million
Wording
Definitive
How definitive the wording is.

Results for this period

Full year
Factors Behind Changes in Business Performance

投資有価証券の一部売却により売却益が発生。理由は保有資産の効率化。

Breakdown of extraordinary income (loss)Item Gain on sale of investment securities / Amount ¥220 million
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Breakdown of extraordinary income (loss)Item Gain on sale of investment securities / Amount ¥220 million
Factors Behind Changes in Business Performance投資有価証券の一部売却により売却益が発生。理由は保有資産の効率化。
Items this document does not state (35)
Accounting standardsConsolidated / non-consolidatedPeriod CoveredNet SalesOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossDisclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To improve the efficiency of our asset holdings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori